Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole

NCT04311671 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

12979

Enrollment

OTHER

Sponsor class

Conditions

Onchocerciasis

Interventions

DRUG: Moxidectin
DRUG: Ivermectin
DRUG: Albendazole

Sponsor

Medicines Development for Global Health